Publikation

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

Wissenschaftlicher Artikel/Review - 01.03.2009

Bereiche
PubMed
DOI

Zitation
Veit O, Furrer H, Hatz C, Staub T, Litzba N, Bae H, Schmid P, Mossdorf E, Cavassini M, Chapuis-Taillard C, Niedrig M, Swiss HIV Cohort Study. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48:659-66.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48
Veröffentlichungsdatum
01.03.2009
eISSN (Online)
1537-6591
Seiten
659-66
Kurzbeschreibung/Zielsetzung

BACKGROUND: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)-infected patients, and adequate immunogenicity and safety are of concern in this population. METHODS: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:>or=10 were defined as reactive, and those of 1:<10 were defined as nonreactive, which was considered to be nonprotective. The results were compared with data for HIV-uninfected individuals. Serious adverse events were defined as hospitalization or death within 6 weeks after receipt of 17DV. RESULTS: At the time of 17DV administration, the median CD4 cell count was 537 cells/mm(3) (range, 11-1730 cells/mm(3)), and the HIV RNA level was undetectable in 41 of 102 HIV-infected patients. During the first year after vaccination, fewer HIV-infected patients (65 [83%] of 78; P = .01) than HIV-uninfected patients revealed reactive NTs, and their NTs were significantly lower (P < .001) than in HIV-uninfected individuals. Eleven patients with initially reactive NTs lost these reactive NTs